pillbase.ru

TAKHZYRO

Active substance: lanadelumab

SOLUTION · LANADELUMAB 150 mg/mL

United StatesActive

Marketing holder: Takeda Pharmaceuticals America, Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 1
  • Takhzyro
    lanadelumab
    EMEA/H/C/004806
    Takeda Pharmaceuticals International AG Ireland Branch
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208f-bc13-7d3b-9f82-62c53490a6ba,01a12095-de1c-74e3-a55d-33e295649b67;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
47783-645
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 47783-645 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 47783-645 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 47783-645 · Verified 2026-10-09 · open in source